Sanofi outlines business priorities up to 2015

Sanofi has outlined its business objectives for the next four years, a period that will see it aiming to maintain sustainable growth in the face of changing industry conditions.

Since the end of 2008, the company has been adopting a new strategy based on restructuring and refocusing its activities to cope with future challenges, while bolstering its research innovation efforts and pursuit of external growth opportunities.

From now until the end of 2012, the company will be aiming to mitigate the impact of key products losing patent protection via consolidated sales from growth platforms, as well as the new capabilities offered by its acquisition of Genzyme.

Thereafter, Sanofi will continue its work on innovative research projects and tighten cost control, allowing it to deliver average annual sales growth of five percent between 2012 and 2015.

Sanofi chief executive officer Christopher Viehbacher said: "Sanofi has undergone an impressive transformation over the last two-and-a-half years and the patent cliff is now almost behind us."

Earlier this month, the company strengthened its transformational capabilities with the appointment of Dr David-Alexandre Gros as its new chief strategy officer.